<DOC>
	<DOCNO>NCT02097095</DOCNO>
	<brief_summary>This independent optional sub-study parallel TB-018 ( NCT01755598 ) biological sample collect future investigation biological correlate , marker prognostic factor TB disease . Subjects consent enroll TB-018 , `` A phase IIb , double-blind , randomise , placebo-controlled study evaluate efficacy , safety immunogenicity GSK Biologicals ' candidate tuberculosis ( TB ) vaccine GSK 692342 ( M72/AS01E ) TB disease , healthy adult age 18-50 year , live TB endemic region '' , ( see NCT 01755598 ) ask participate sub-study . Subjects enrol TB-018 also consent C-041-972 follow accord TB-018 protocol additional blood sample collect sub-study .</brief_summary>
	<brief_title>Substudy Protocol TB-018 ( NCT01755598 ) : Collection Storage Biological Samples Evaluation Correlates TB ( C-041-972 )</brief_title>
	<detailed_description>Additional information protocol</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>To eligible substudy , subject must enrol TB018 provide separate write informed consent C041972 . See NCT 01755598 inclusion criterion TB018 . Exclusion criterion : To eligible substudy , subject must enrol TB018 provide separate write informed consent C041972 . See NCT 01755598 exclusion criterion TB018 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Correlates risk</keyword>
	<keyword>TB</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Sub-study</keyword>
	<keyword>TB-018</keyword>
</DOC>